Seeking Alpha

More on Amgen (AMGN) / Micromet (MITI) deal: The acquisition provides Amgen with blinatumomab, a...

More on Amgen (AMGN) / Micromet (MITI) deal: The acquisition provides Amgen with blinatumomab, a leukemia treatment in Phase 2 trials. The offer of $11/share is a 33% premium to Micromet's close yesterday. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector